Prostate Specific Antigen Changes as Related to the Initial Prostate Specific Antigen: Data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
E. David Crawford(University of California San Diego), John K. Gohagan(National Institutes of Health), David Chia(University of California, Los Angeles), Edward P. Gelmann(University of Arizona), Paul F. Pinsky(National Cancer Institute), Gerald L. Andriole(Institut thématique Génétique, génomique et bioinformatique), Richard M. Fagerstrom(United States Department of Health and Human Services), Douglas J. Reding(Ascension), Barnett S. Kramer(University of Pittsburgh), David L. Levin(University of California San Diego)
Cited by 30
Related Papers
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
|Nature Genetics|2007|1.1k
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
|Controlled Clinical Trials|2000|1k